During the last session, Zai Lab Limited ADR (NASDAQ:ZLAB)’s traded shares were 0.78 million, with the beta value of the company hitting 1.09. At the end of the trading day, the stock’s price was $28.84, reflecting an intraday loss of -0.33% or -$0.09. The 52-week high for the ZLAB share is $39.77, that puts it down -37.9 from that peak though still a striking 53.26% gain since the share price plummeted to a 52-week low of $13.48. The company’s market capitalization is $3.16B, and the average intraday trading volume over the past 10 days was 2.11 million shares, and the average trade volume was 1.17 million shares over the past three months.
Zai Lab Limited ADR (ZLAB) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.29. ZLAB has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
Zai Lab Limited ADR (NASDAQ:ZLAB) trade information
Zai Lab Limited ADR (ZLAB) registered a -0.33% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.33% in intraday trading to $28.84, hitting a weekly high. The stock’s 5-day price performance is 18.59%, and it has moved by -24.13% in 30 days. Based on these gigs, the overall price performance for the year is 100.00%. The short interest in Zai Lab Limited ADR (NASDAQ:ZLAB) is 7.32 million shares and it means that shorts have 7.5 day(s) to cover.
The consensus price target of analysts on Wall Street is $55, which implies an increase of 47.56% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $55 and $55 respectively. As a result, ZLAB is trading at a discount of -90.71% off the target high and -90.71% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -3.18%. While earnings are projected to return 43.28% in 2025.
ZLAB Dividends
Zai Lab Limited ADR is due to release its next quarterly earnings on 2025-Feb-26. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Zai Lab Limited ADR (NASDAQ:ZLAB)’s Major holders
Zai Lab Limited ADR insiders own 1.44% of total outstanding shares while institutional holders control 54.55%, with the float percentage being 55.34%. PRICE T ROWE ASSOCIATES INC /MD/ is the largest shareholder of the company, while 188.0 institutions own stock in it. As of 2024-06-30, the company held over 1.66 million shares (or 1.7037% of all shares), a total value of $28.73 million in shares.
The next largest institutional holding, with 7.12 million shares, is of WELLINGTON MANAGEMENT GROUP LLP’s that is approximately 0.73% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $123.47 million.
Also, the Mutual Funds coming in first place with the largest holdings of Zai Lab Limited ADR (ZLAB) shares are New World Fund Inc and VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund. Data provided on Jan 31, 2025 indicates that New World Fund Inc owns about 3.28 shares. This amounts to just over 2.99 percent of the company’s overall shares, with a $94.59 million market value. The same data shows that the other fund manager holds slightly less at 2.9, or about 2.64% of the stock, which is worth about $83.52 million.
